Sept. 29, 2017 (TORONTO and ST. LOUIS) — CCRM, a leader in the development and commercialization of regenerative medicine technologies, cell and gene therapies and Affigen, a biotechnology company that is developing therapeutics that target cell lineage-specific tumor proteins, are pleased to announce a new partnership that will advance the creation and commercialization of a closed platform for the production of individualized, tumor-identifying therapeutics for the treatment of a range of currently incurable cancers.
Funding for Development of Cancer Immunotherapies Targeting Cell Lineage-Specific Tumor Proteins
Feb. 21, 2017 (ST. LOUIS and HOUSTON) — Affigen, a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, today announced the closing of a $17 million Series A financing round led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC.
We’re hiring! Affigen has several open positions, and we’re looking for talented individuals across all areas of the company to help us achieve our goals.
+1 (314) 254-5081
20 S. Sarah St.
Saint Louis, MO 63108